Other
Olaparib (brand name: Lynparza, Lipuzhuo; Beacon).
Price range: £468.00 through £591.00Olaparib produced by Beacon (generic name: Olaparib; brand names: Lynparza, Lipuzhuo) is a PARP inhibitor originally developed by AstraZeneca. It has been approved by the FDA for the treatment of various cancers, including ovarian cancer, breast cancer, prostate cancer, and pancreatic cancer.
It works by inhibiting DNA repair enzymes, preventing cancer cells from repairing their DNA, which leads to cell death and helps delay or stop tumor progression.
Beacon Pharmaceuticals was founded in 2001 and is one of the largest and most technologically advanced manufacturers of oncology and antiviral drugs in Bangladesh. Its products comply with international GMP certifications, including those from the US FDA, UK MHRA, and Australia’s TGA.
Osimertinib (brand name: Tagrisso, Terisha; Incepta).
Original price was: £288.00.£97.00Current price is: £97.00.由 Incepta 公司生产的奥希替尼是一种第三代口服不可逆 EGFR 靶向酪氨酸激酶抑制剂 (EGFR-TKI)，由英国阿斯利康公司开发。其原商品名为泰瑞沙 (Tagrisso)，研发代号为 AZD9291。
它用于治疗晚期非小细胞肺癌（NSCLC），并选择性地抑制 EGFR 敏感突变和 EGFR T790M 耐药突变。
